Radiopharmaceuticals are highly specialized and require equipment, facilities, personnel, licensing and training that is significantly different from traditional pharmaceutical manufacturing.
SHINE Medical Technologies is building a plant in Wisconsin to produce a vital radioactive isotope called molybdenum-99, a vital radioactive isotope used to detect cancer and other potentially fatal maladies in millions of people every year.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A biotechnology company’s licensing deal for a radiopharmaceutical could make it easier to diagnose acute coronary syndrome in cases that might otherwise go undiagnosed or be diagnosed too late. Molecular Targeting Technologies acquired the license for the radiopharmaceutical diagnostic imaging agent from the Medical College of Wisconsin, according to a company statement. It is used in […]